Health
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) – Business Wire
Moderna announces publication of interim results from older adult age cohorts in Phase 1 study of its mRNA vaccine in NEJM.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, inThe New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart…
-
Noosa News24 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General20 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
Noosa News19 hours agoColombian Director Simón Mesa Soto’s ‘A Poet’ Is 2025’s Winner of Melbourne International Film Festival’s Bright Horizons Award